NCT03822260

Brief Summary

The investigators are planning that can these markers be used a predictive marker at SAH and for this aim we will study both patiens' blood sample and their CT image.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
54

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2017

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

November 12, 2018

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2019

Completed
29 days until next milestone

First Posted

Study publicly available on registry

January 30, 2019

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2019

Completed
Last Updated

January 30, 2019

Status Verified

January 1, 2019

Enrollment Period

2 years

First QC Date

November 12, 2018

Last Update Submit

January 28, 2019

Conditions

Subarachnoid Hemorrhage, Aneurysmal

Outcome Measures

Primary Outcomes (1)

  • Diagnostic marker identification

    Evaluation of the concentration levels of enflamation markers relation with Sur1 TRPM+ molecules, together with the values of global tests of coagulation system, may serve as a helpful SAH diagnostic marker.

    24 months

Study Arms (1)

Sur1/ Trpm 4 acitivities at SAH

only after collecting sample,

Diagnostic Test: Bezmialem VAkif Unv. Ethical board

Interventions

Bezmialem VAkif Unv. Ethical boardDIAGNOSTIC_TEST

If ıs any trials not convenient to Helsinki Agrement about Human research rules

Sur1/ Trpm 4 acitivities at SAH

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients admitted to the emergency room of the universty hospital with aSAH have a CBC and blood sample performed on admission. Blood samples are obtained significant days (1,4-14 days) thereafter during their hospitalization.

You may qualify if:

  • Ruptured Subarachnoid Aneursym

You may not qualify if:

  • without aneursymal sah
  • Patient's positive for rheumatoid factor and anti-CCP or with chronic inflammatory diseases (such as ankylosing spondylitis or rheumatoid arthritis), systemic diseases (such as hypercholesterolemia, hypertension, diabetes mellitus, myocardial infarction, stroke, peripheral artery disease), active infection, a history of term medication, trauma to the hip and smoking were excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

In the blood plasma stored in the temperature of -86 'C for the period not longer than 6 months, the concentration of the following parameters was marked with the use of immunoenzymatic ELISA method

MeSH Terms

Conditions

Subarachnoid Hemorrhage

Condition Hierarchy (Ancestors)

Intracranial HemorrhagesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 12, 2018

First Posted

January 30, 2019

Study Start

January 1, 2017

Primary Completion

January 1, 2019

Study Completion

June 1, 2019

Last Updated

January 30, 2019

Record last verified: 2019-01